Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer ; volume:21 ; number:1 ; day:23 ; month:7 ; year:2021 ; pages:1-9 ; date:12.2021
BMC cancer ; 21, Heft 1 (23.7.2021), 1-9, 12.2021

Urheber
Chen, Jiayuan
Hua, Qingling
Wang, Haihong
Zhang, Dejun
Zhao, Lei
Yu, Dandan
Pi, Guoliang
Zhang, Tao
Lin, Zhenyu
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12885-021-08605-x
URN
urn:nbn:de:101:1-2021102400481895400907
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:22 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Chen, Jiayuan
  • Hua, Qingling
  • Wang, Haihong
  • Zhang, Dejun
  • Zhao, Lei
  • Yu, Dandan
  • Pi, Guoliang
  • Zhang, Tao
  • Lin, Zhenyu
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Pankreaskarzinom nab-Paclitaxel

Pankreaskarzinom nab-Paclitaxel

Breast cancer nab-Paclitaxel

Breast cancer nab-Paclitaxel

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study

Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer

Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer

Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)

Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer

Neoadjuvant nab-paclitaxel in the treatment of breast cancer

Neoadjuvant nab-paclitaxel in the treatment of breast cancer

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Verbundene Objekte